AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior listings and versions.

1-39. Cancelled

40. (Currently amended) An expression vector useful for immunizing a host comprising nucleic acid sequences encoding modified KSA (SEQ ID NO.: 15).

41. (Previously presented) The expression vector of claim 40 wherein the vector is a plasmid or a viral vector.

42. (Previously presented) The expression vector of claim 41 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.

43. (Previously presented) The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

44. (Previously presented) The expression vector of claim 43 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

45. (Previously presented) The expression vector of claim 40 further comprising at least one additional tumor associated antigen.

46. (Currently amended) The expression vector of claim 45 wherein the tumor associated antigen is selected from the group consisting of carcinoembryonic antigen (SEQ ID NO.:5), a modified carcinoembryonic antigen (SEQ ID NO.: 4), or p53 (SEQ ID NO.:2).

47. (Previously presented) The expression vector of claim 40 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

48. (Previously presented) The expression vector of claim 47 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.

49. (Previously presented) A composition comprising an expression vector of claim 40 in a pharmaceutically acceptable carrier.

50. Cancelled

51. (Previously presented) An isolated DNA molecule encoding SEQ ID NO.: 15.

52-59. Cancelled

60. (New) An isolated nucleic acid molecule comprising SEQ ID NO.: 20.